Bellus Health, a small Canadian drug maker, is seeking to develop a potential blockbuster medicine for chronic cough that could surpass a competing drug from Merck.
Now, it’s nearing the completion of a mid-stage clinical trial that will serve as a pivotal test of whether it can pull that off.
Here are five things to know about the Bellus drug, its Phase 2 study, and expectations heading into the results.
About the Author Reprints
